{"id":116208,"date":"2026-02-25T19:09:23","date_gmt":"2026-02-25T19:09:23","guid":{"rendered":"https:\/\/mailinvest.blog\/index.php\/2026\/02\/25\/indivior-returns-to-havas-with-u-s-aor-assignment\/"},"modified":"2026-02-25T19:10:23","modified_gmt":"2026-02-25T19:10:23","slug":"indivior-returns-to-havas-with-u-s-aor-assignment","status":"publish","type":"post","link":"https:\/\/mailinvest.blog\/index.php\/2026\/02\/25\/indivior-returns-to-havas-with-u-s-aor-assignment\/","title":{"rendered":"Indivior Returns to Havas With U.S. AOR Assignment"},"content":{"rendered":"

<\/a>\n<\/p>\n

\n

Indivior, which develops long-acting injectable remedies for opioid use dysfunction (OUD), has consolidated artistic, media, and digital duties with Havas. McKinney beforehand dealt with artistic and Click on Well being oversaw media and digital, in keeping with sources accustomed to the account.<\/p>\n

Havas will lead built-in technique, artistic, media, and digital efforts throughout each healthcare skilled (HCP) and direct-to-consumer (DTC) audiences. The account will likely be managed throughout Havas Life New York, Havas Media Community, and Havas CX below a single P&L, with Chris Schnurman, managing director of Havas Life New York, serving as govt sponsor. <\/p>\n

COMvergence estimates Indivior\u2019s 2025 U.S. media spend at $60 million.<\/p>\n

Havas beforehand labored with Indivior by means of its shopper well being group Jacques NY (previously Havas Tonic) earlier than the account moved to McKinney in 2023. The income from this expanded partnership is \u201ccompletely incremental,\u201d mentioned Schnurman, and marks a return to the roster with a broader remit.<\/p>\n

The brand new company mannequin follows management change at Indivior, together with the appointment of CEO Joe Ciaffoni, because it refocuses on rising its long-acting injectable remedies in a class marked by stigma, regulation, and sophisticated affected person journeys.<\/p>\n

\u201cIndividuals with opioid use dysfunction are very troublesome to seek out. Their mindset and their readiness to tackle remedy modifications every day,\u201d Schnurman mentioned. \u201cDiscovering these individuals on the proper time with the suitable message and getting them linked to the suitable doctor requires an entire lot of coordination.\u201d<\/p>\n

For Havas, the project displays an ongoing effort to function built-in artistic, media, and expertise groups. The holding firm created its village mannequin in 2017, bringing Havas Inventive and Havas Media below a single P&L, and in 2022 merged Havas Inventive with Havas Well being below CEO Donna Murphy.<\/p>\n

\u201cIndivior didn\u2019t come to us for an promoting resolution; they got here to us for integration,\u201d Greg James, CEO of Havas Media Community North America, advised ADWEEK. <\/p>\n

He added that whereas the important thing objective is to drive simpler work, efficiencies are to be gained as nicely. \u201cYou typically will see efficiencies and value financial savings as a result of there\u2019s much less duplication,\u201d he mentioned.<\/p>\n

\n
\n
\"teaser-image\"<\/a> <\/div>\n<\/section>\n<\/div>\n

<\/p>\n

He added that Pharma carries extra regulatory and operational nuance in contrast with different classes, making an integration like this for Indivior extra advanced.<\/p>\n

\u201cIt\u2019s extra technically nuanced,\u201d James mentioned. \u201cIf you concentrate on the approvals course of for pharma, the regulatory surroundings from a expertise perspective, you\u2019ve acquired to ensure that all people actually understands these nuances and variations.\u201d<\/p>\n

The Indivior win bolsters Havas\u2019 momentum within the healthcare sector, following a 12 months through which the company mentioned it secured 20 new media purchasers, 4 of which had been within the pharma and well being, together with Collegium Pharmaceutical.<\/p>\n

\u201cIt\u2019s considered one of our highest progress areas, and continues to be,\u201d James mentioned.<\/p>\n<\/div>\n